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Setting up the only vaccine 
manufacturing facility in 
Southern Africa
















All three facilities terminated production of vaccines between 1995-2001
Due to:
• Lack of  relevant skills
• Lack of capital
• Increasing regulation 
• Lack of adaptation with new technologies
• Lack of GMP culture/ lack of willingness to adopt GMP










Source: World vaccines, 2007
However………………….
The need for human vaccines in 






Options at the time……
1. Shut down completely or
2. Privatise or
Partner with the  private sector
THE BIOVAC INSTITUTE
A Public Private Partnership
Vision and Objectives
To be a Centre of 
Excellence routed in 














Develop and retain 
local vaccine 
production skills




1. Source & Supply 
EPI vaccines 




- Commence Vaccine 
manufacture
- Implement Technology 
Phase II 
2003-08 2008-13 2013-
- New manufacturing 
facility




- Attract Technology 
Transfers
Transfers 
- Invest in new 
Technology platforms
- Expansion of the site
- New Warehouse and 
Cold rooms
Phase I 
- Basic R&D 
- Establsih basic Quality 
Control infrastructure
- Establish Labelling & 
Packaging & Cold 
Chain capacity
- Recruit expertise 
Biovac Headcount Projection
Perm Staff Only
2008 – 2011: 27% increase on headcount
2011 – 2012: 26% proposed increase 




























T I M E L I N E
Staff requirements 
• Vaccine (biological) production regulation standards are increasing 
globally 
• This requires more skills and higher level skills to maintain global 
standards 
• Presence of practical versus theoretical experience 
• Experienced skills are expensive and difficult to attract 
• Largest pool of global vaccine skills are located in Europe and Asia 
• Innovation is needed to attract skills 
Status Biovac Institute 
  2013 2013
Status 2012 
2013
Existing GMP pilot scale lab 
New Manufacturing facility 2012 
Expansion of Warehouse & 
Cold rooms and Packaging  
2013 
Facility built in 2005



























Building D: Development Labs
 BSL3 – Fermentation
 DSP / Conjugation /AMD
Building B: Pilot GMP – Clinical Material
Conjugate Platform
Hib
• Hib development process commenced in 2006/7 aimed at developing a Hib conjugate suitable 
for use in fully liquid combination vaccines.
• Conjugate chemistry – based on NIH technology.  Conjugate chemistry chosen for it’s stability 
and relative higher yields to previous conjugate processes
• Stability good as liquid.  Data up to 24 months real time. 
• Immunogenicity in animals is good - compared very well to commercial conjugate
• Transferred to two international vaccine companies
Pneumo
• Project funded by PATH
• Development of processes for tech transfer to CDIBP
• Fermentation and purification of 3 serotype
• Conjugation of 3 serotypes
• Test different protein carriers 
Influenza Project
WHO Technology Transfer Initiative
Objectives:
• Help developing countries to develop 
influenza vaccine manufacturing capabilities 
and capacity for pandemic readiness
• Help achieve sustainable influenza vaccine 
production capacity
Flu vaccine capacity lacking 
in Sub-Saharan African 
19
Flu Project
Immediate Objective Longer term Objective
• Source a technology 
transfer partner and 
supplier of formulated bulk
• Identify a relevant modern 
technology compatible 
with our capacity in order 
• Establish local capability 
for filling of both seasonal 
and pandemic influenza 
vaccine.




• Regulatory - MCC ( a PIC/S member)
• Universities: Internationally recognised 
• Clinical trial Infrastructure: well established
• A clear biotechnology mandate 
Biovac capability
• GMP facilities for production ready in 2013
• GMP facilities for pilot scale manufacture
• Established cold chain capability
• Know-how in fermentation, conjugation platforms 
In Summary: capability exists in Southern 
Africa!




























































































































Technology Transfer Products into Facility
Product registration to MCC& ultimately WHO
Thank you
